Home > Receptors & Transporters > Glutamate > AMPA & Kainate > Kainic acid 

Kainic acid

Prototypic kainate receptor agonist.

Other names: Kainate

Product Code: Asc-100

Purity: >99%

 
Pack Size

 

1mg

10mg

50mg

Buy Kainic acid from Abcam
Biological Description

Prototypic agonist at the kainate class of ionotropic glutamate receptors. Potent excitant and neurotoxin, used to model epilepsy and neurodegenerative states. Also available in Low-Cost Kit(s): Ionotropic agonists (Asc-323).

Useful References

(2005) Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol. 31:3-16. abstract

(1998) The activation of glutamate receptors by kainic acid and domoic acid. Nat.Toxins. 6:153-8 abstract

(1981) Minireview. Kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci. 29:2031-42 abstract

Citations

Milstein et al. (2007) TARP subtypes differentially and dose-dependently control synaptic AMPA receptor gating. Neuron. 55: 905-18. abstract

Lee et al. (2008) Temporal expression of AMP-activated protein kinase activation during the kainic acid-induced hippocampal cell death. J of Neural Transmission. 116: 33-40. abstract

Feligioni et al. (2009) Protein SUMOylation modulates calcium influx and glutamate release from presynaptic terminals. EJN 29: 1348-1356 abstract

Cyclin D1 in excitatory neurons of the adult brain enhances kainate-induced neurotoxicity abstract

Paper de la GSK-3 i la JNK en la regulació de les vies apoptòtiques en cèl. lules granulars de cerebel abstract

Predominant functional expression of Kv1. 3 by activated microglia of the hippocampus after Status epilepticus abstract

Vibrational spectroscopic investigation of the ligand binding domain of kainate receptors abstract

AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity abstract

Astrocytic activation and an inhibition of MAP kinases are required for proteinase‐activated receptor‐2‐mediated protection from neurotoxicity abstract

Dynamics of early locomotor network dysfunction following a focal lesion in an in vitro model of spinal injury abstract

Hydrophobic side chain dynamics of a glutamate receptor ligand binding domain abstract

Excitotoxicity through Ca< sup> 2+-permeable AMPA receptors requires Ca< sup> 2+-dependent JNK activation abstract

Phosphorylation of 14-3-3ζ at serine 58 and neurodegeneration following kainic acid-induced excitotoxicity abstract

The transmembrane domain C of AMPA receptors is critically involved in receptor function and modulation abstract

Enhanced integration of newborn neurons after neonatal insults abstract

Mechanism of AMPA Receptor Activation by Partial Agonists abstract

Inverse relationship of cannabimimetic (R+) WIN55, 212 on behavior and seizure threshold during the juvenile period abstract

Piperazine-2, 3-dicarboxylic Acid Derivatives as Dual Antagonists of NMDA and GluK1-Containing Kainate Receptors abstract

Differential DNA methylation patterns define status epilepticus and epileptic tolerance abstract

The effects of acute responsive high frequency stimulation of the subiculum on the intra‐hippocampal kainic acid seizure model in rats abstract

Antioxidants and free radical scavengers do not consistently delay seizure onset in animal models of acute seizures abstract

AMPA receptor ligand binding domain mobility revealed by functional cross linking abstract

Mixed inhibitory synaptic balance correlates with glutamatergic synaptic phenotype in cerebellar unipolar brush cells abstract

Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H] UBP310 abstract

Neuronal network formation from reprogrammed early postnatal rat cortical glial cells abstract

Chemical Information

(2S,3S,4S)-3-(Carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid

Asc-100
  • Desiccate at +4°C
  • MW 213.23
  • Soluble in water to 25 mM
  • C10H15NO4
  • 58002-62-3